Acute Porphyria Drug Database

R03AK04 - Salbutamol and Sodium Cromoglicate
Propably not porphyrinogenic
PNP

Rationale
salbutamol: Rather low dose, in large parts excreted unmetabolized. No data pointing to clinical CYP-interaction. Four references consider it safe. ipratropium: Hydrophilic substance, insignificant systemic exposure.
Chemical description
(To be edited, initial data ST OCT 04) salbutamol: Adrenergic beta-receptor stimulating agent used in asthma. Administered as salbutamol sulfate in micronized form in inhalation aerosol (2,5 - 5 mg/dose). No clinical data pointing to CYP-interaction. About 35% of the dose is excreted in unchanged form in urine. ipratropiumbromide Ipratropiumbromide, a quarternary ammonium compound with anticholinergic properties. used in inhalation aerosol (21-42 ug/dose) as bronchodilator in chronic obstructive pulmonary disease and in asthma. No data poiinting to CYP-interaction. salbutamol: EPI-list: safe South African list: use French list: authorized. Kauppinen and Mustajoki. Prognosis of acute porphyria... Medicine 1992; 71: 1-13: tolerated (n=2)
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes R03A / R03AK or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙